[
  {
    "ts": null,
    "headline": "Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD",
    "summary": "On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion, RVO, and for broadening the dosing schedule to include every 4-week dosing across approved indications. The FDA target action date is August 19, 2025, following the use of a Priorit",
    "url": "https://finnhub.io/api/news?id=46efb67d26402fdbd67b97341473bb9823fc67b2e0877ad611ec05feaad02ea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745076307,
      "headline": "Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD",
      "id": 134023042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion, RVO, and for broadening the dosing schedule to include every 4-week dosing across approved indications. The FDA target action date is August 19, 2025, following the use of a Priorit",
      "url": "https://finnhub.io/api/news?id=46efb67d26402fdbd67b97341473bb9823fc67b2e0877ad611ec05feaad02ea4"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi announce FDA approval of Dupixent for CSU",
    "summary": "Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark",
    "url": "https://finnhub.io/api/news?id=be8dee19facb8bfc3682c4d6eb16176c55e0b3ccf100d25594d298c0cf6d22af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745076009,
      "headline": "Regeneron, Sanofi announce FDA approval of Dupixent for CSU",
      "id": 134023043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark",
      "url": "https://finnhub.io/api/news?id=be8dee19facb8bfc3682c4d6eb16176c55e0b3ccf100d25594d298c0cf6d22af"
    }
  }
]